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Context: Infertility affects 10–15% of couples worldwide and tubal factor is a major component in sub‑Saharan Africa. Pelvic 
inflammatory disease due to chlamydia infection is a known risk factor for tubal infertility.
Objective: This case‑control study was carried out to determine the relationship between chlamydial infection and infertility 
as seen at the Lagos University Teaching Hospital, Lagos, Nigeria.
Methodology: This was a case‑controlled study of 180 participants recruited from the Gynaecology Outpatient and Family 
Planning Clinics of the Lagos University Teaching Hospital, Lagos, Nigeria (LUTH). The cases were 60 females diagnosed 
to have tubal infertility and 60 other infertile females with patent tubes. The control group comprised of 60 females attending 
the family planning clinic. The females were tested for serum chlamydia IgG antibody using a kit that detects serovar specific 
Chlamydia trachomatis antibody. Endocervical swab samples were also tested for chlamydial antigen using a kit that detects 
C. trachomatis genus specific lipopolysaccharide antigen. The results were collated and analyzed using the statistical package 
for the social sciences (SPSS) version 18.
Results: All the females tested negative for chlamydia antigen. The odd ratio for having a case testing positive for chlamydial 
antibody compared to control was 4.0 [95% CI = 1.47–10.88]. The odd ratio for infertile females with blocked tubes compared 
with those who had patent tubes testing positive for chlamydia antibody was 3.52 (95% CI: 1.46–8.49).
Conclusion: This study suggests an etiological relationship between chlamydial infection and infertility in general and tubal 
infertility in particular.
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Introduction
The clinical, financial, and psychological burden of infertility, 
in any society is enormous. The psychological burden is 
more pronounced in traditional societies like Nigeria where 
much premium is placed on child bearing. The contribution 
of tubal pathology to infertility varies across populations. 
Genital C. trachomatis infection is one of the most prevalent 
sexually transmitted infections and pelvic inflammatory 
disease (PID) from chlamydia infection is a major risk 
factor for tubal infertility.[1] Chlamydial cervicitis has also 
been suggested to contribute to unexplained infertility by 
yet to be fully determined mechanism.[2] In males, genital 
chlamydial infection is asymptomatic in about 50% of 
cases[1] and is associated with male infertility.[3] Chlamydial 
infection is thus probably the most important preventable 
cause of infertility.
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Owing to the increasing prevalence of chlamydial infection, 
its often asymptomatic course and the potential for serious 
complications especially infertility, screening programs have 
been developed in industrialized nations to reduce the rate 
of PID and other reproductive sequelae.[1,4] Ironically in 
Africa where the prevalence of infection and tubal infertility 
is perceived to be high, there are no population screening 
programs. Females attending for gynecological procedures 
and work-up for infertility like hysterosalpingogram (HSG) and 
laparoscopy and chromotubation are not routinely screened 
for chlamydia. This makes the magnitude of the problem 
unclear but potentially huge. Furthermore, procedures like 
dilatation and curettage and insertion of intrauterine devices 
are carried out without screening or prophylactic treatment 
for chlamydia. This may disseminate existing cervical 
infection to the pelvis or worsen preexisting pelvic infection.
Despite the high prevalence of infertility in Nigeria and the 
recognised contribution of PID to tubal infertility, very limited 
local data exist on the contribution of genital chlamydia 
infection to infertility generally and tubal infertility in 
particular. Elsewhere, studies have demonstrated significant 
correlation between past chlamydia infection and infertility[5,6] 
and some studies have shown an association between active 
infection and infertility.[7]
This study was carried out to determine the relationship 
between chlamydial infection and tubal infertility as seen at 
the Lagos University Teaching Hospital, Lagos, Nigeria (LUTH). 
The study aims to determine the prevalence of current 
and past chlamydial infection in females with and without 
infertility and establish any relationship between chlamydia 
infection and tubal infertility.
Methodology
The study was a case-controlled study carried out at the 
Lagos University Teaching Hospital between 1st March and 
30 September 2012. A total of 180 participants were recruited 
from the Gynaecology Outpatient and Family Planning 
Clinics of the Lagos University Teaching Hospital, Lagos, 
Nigeria (LUTH). The participants consisted of 60 females 
diagnosed to have tubal infertility and 60 other infertile 
females with patent tubes attending the gynecology clinic. 
The control group comprised of 60 females without history 
of infertility attending the family planning clinic but not yet 
on any contraceptive method. Ethical approval for the study 
was obtained from the Lagos University Teaching Hospital 
Health Research and Ethics Committee (LUTH-HREC). All 
consecutive females attending the gynecology clinic and 
the family planning clinic, respectively, during the study 
period who met the inclusion criteria were approached and 
requested to participate in the study. A written informed 
consent was obtained from each participant.
A pro forma was used to collect relevant sociobiological and 
clinical data for each participant including age, parity, and 
clinical diagnosis. The results of laboratory tests carried out 
were later entered into the pro forma.
Five milliliters of venous blood was drawn from each 
patient and serum was prepared from each sample using 
standard techniques. The serum samples were stored in 
the Central Research Laboratory at ‒20°C till it was time 
for analysis. Chlamydia antibody (IgG) testing was carried 
out on sera collected from each participant using the DIA. 
PRO kit. This detects serovar specific Chlamydia trachomatis 
antibody using microplate coated with immuno-dominant 
species-specific C. trachomatis major outer-membrane protein 
antigen (MOMP). An optical signal that was proportional to 
the level of antibody present was generated using this kit. The 
optical density (OD) was measured at 450 nm. The OD cutoff 
value of 0.3 was determined using the calibrators provided 
with the kit. The samples were considered positive when the 
absorption value was higher than the cutoff.
An endocervical swab was also collected from each 
participant using standard technique. Chlamydia antigen 
testing was carried out on the endocervical sample 
using the DiaSpot Chlamydia kit. This works on the 
principle of detection of C. trachomatis genus specific 
lipopolysaccharide (LPS) antigen. The method employs 
the principle of monoclonal antibody testing with high 
specificity (97%) and sensitivity (90%). The results were 
entered into the pro forma for each participant.
Data from the pro forma were fed into an electronic database 
designed on Microsoft Access. Data analysis was carried out 
using the SPSS Statistics for Windows Version 18.0, (SPSS Inc., 
Chicago, USA). Frequency analysis was run and cross tables 
constructed. Significance in the outcome was verified using 
the Chi-square test.
Results
The females with infertility (cases) were aged between 22 and 
45 years, their mean age was 33.2 (±2.1) years. Females in the 
control group were aged between 27 and 42 years, their mean 
age was 36.3 (±2.3) years. Table 1 shows the distribution 
of the cases of infertility according to whether they were 
primary or secondary; and whether the tubes were patent 
or blocked. Among the females with infertility, 89 (74.2%) 
had secondary infertility whereas the remaining 31 (25.8%) 
had primary infertility. Majority (56.2%) of the females with 
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secondary infertility had tubal blockage whereas only 32.3% 
of those with primary infertility had tubal blockage. The odd 
ratio for having blocked tubes in females with secondary 
infertility compared to those with primary infertility was 
2.692 (95% CI = 1.137–6.373).
Table 2 shows the results of chlamydial antibody test for 
the cases and control groups. Thirty-two (26.7%) of the 
cases tested positive for chlamydial antibody whereas only 
five (8.3%) of the control group were positive for antibody. The 
odd ratio for having a case positive for chlamydial antibody 
compared to control was 4.0 (95% CI = 1.47–10.88). The odd 
ratio of positive chlamydia antibody in secondary compared 
with primary infertility was 1.45 (95% CI = 0.6–3.5) [Table 3]. 
Table 4 shows distribution of chlamydial antibody in infertility 
patients with blocked and patent tubes, respectively. 
Twenty-three (38.3%) of patients with tubal blockage and 
nine (15.0%) of those with patent tubes, respectively, tested 
positive for chlamydial antibody. The odd ratio for infertile 
females with blocked tubes compared with those who had 
patent tubes testing positive for chlamydia antibody was 
3.52 (95% CI: 1.46–8.49).
It is notable that none of the females (in both cases and 
control groups) tested positive for chlamydial antigen 
indicating zero prevalence of active chlamydial infection.
Discussion
This study showed that none of the females attending the 
infertility clinic (cases) or family planning clinic (control group) 
had evidence of active chlamydial infection as they tested 
negative for chlamydia antigen. This is not surprising giving 
that the mean age of the females were 33.2 (±2.1) years 
and 36.3 (±3.2) years, respectively. However, the study 
demonstrated that 37 (20.6%) of the females tested positive 
for chlamydia antibody. It also found that 26.7% of the 
females with infertility tested positive for chlamydia antibody 
compared with 8.3% of the control group. Furthermore, among 
the infertility group, 38.3% of those with tubal infertility tested 
positive compared with 15% of those with patent tubes.
It is notable that all the females in the study (both cases 
and controls) tested negative for chlamydial antigen. This 
is consistent with very low prevalence rates that have been 
reported in similar populations elsewhere.[8-11] Although 
the principle of antigen detection using the enzyme 
linked immunosorbent assay (ELISA) against specific 
lipopolysaccharides was used in this study, different 
techniques were used in other studies reviewed. Siemer and 
colleagues recorded a prevalence of 1.6% among infertile 
females using the nucleic acid amplification technique of 
polymerase chain reaction (PCR) in Ghana.[8] Using both ELISA 
and PCR in Iran, researchers observed a 0% prevalence rate 
of chlamydia.[9] Similarly, no antigen was detected by culture 
technique among 105 infertile females in Norway in whom 
fallopian tube specimens were collected at laparoscopy.[10] 
In Aberdeen, in which 427 infertile females were tested, 
no antigen was detected using ELISA technique among 
217 females, but 4 of the remaining 210 females (1.9%) tested 
positive using PCR.[11] The variations in the rates recorded may 
be attributable to the difference in laboratory techniques and 
sociodemographic characteristics of the different populations 
studied.
Nucleic acid amplification tests (NAAT) are expensive and 
not readily available in Nigeria. Similarly, culture techniques 
are expensive and very laborious and have low sensitivity 
but high specificity.[12] Considering the limitations of culture 
and nucleic amplification techniques, the use of ELISA for 
antigen detection can be justified in screening for chlamydial 
infection. It is a more readily available test modality in 
Nigeria, it is cheaper and the expertise required is readily 
available. The kit used in this study (DiaSpot Chlamydia) has 
a quoted sensitivity of 90% and a specificity of 97% relative 
to PCR.
Studies in Nigeria that have examined the prevalence of active 
genital chlamydia infection are few and have used diverse 
Table 1: Tubal status in primary and secondary infertilities
Tubal status Primary infertility (%) Secondary infertility (%)
Tubes patent 21 (67.7) 39 (43.8)
Tubes blocked 10 (32.3) 50 (56.2)
Total 31 89
Table 2: Chlamydia antibody in infertility and control groups
Chlamydia antibody Infertility 
cases (%)
Control group (%)
Positive 32 (26.7) 5 (8.3)
Negative 88 (73.3) 55 (91.7)
Total 120 60
Table 3: Chlamydia antibody and type of infertility
Chlamydia antibody Primary infertility (%) Secondary infertility (%)
Positive 10 (32.3) 22 (24.7)
Negative 21 (67.7) 67 (75.3)
Total 31 89
Table 4: Chlamydia antibody in infertile females with patent and 
blocked fallopian tubes
Chlamydia antibody Blocked tubes (%) Patent tubes (%)
Positive 23 (38.3) 9 (15.0)
Negative 37 (61.7) 51 (85.0)
Total 60 60
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study population. Researchers working in northern Nigeria, 
reported a prevalence rate of 9% in a population of females 
with an average age of 24 years attending gynecology and 
antenatal clinics whereas a prevalence of 11% was reported 
among sexually active undergraduates less than 30 years in the 
south.[13,14] A prevalence rate of 6.5% was reported in Lagos by 
Aladesanmi and coworkers among antenatal patients with mean 
age of 25 years.[15] Age is an important risk factor for genital 
chlamydial infection.[1,4] The Centre for Disease Control (CDC) 
reported the peak age of infection as 15–24 years.[4] This 
age-related risk is probably associated with having new sexual 
partners, multiple sexual partners, and inconsistent use or 
outright failure to use barrier contraceptives. The mean age 
of the study population (infertile females) was 33.2 years and 
36.3 years for the control group. The mean age in this study 
is similar to that of the Iranian study where the average age 
of the 96 infertile females studied was 30 years and none of 
them tested positive for chlamydial antigen by both ELISA 
and PCR techniques.[9] The populations in which some antigen 
positivity was recorded tend to be younger.[13-15] It is probable 
therefore that genital chlamydial infection acquired in the 
adolescent/earlier years had resolved leaving behind the 
sequelae of tubal damage and/or infertility. Also all females 
studied were married and presumably in restricted sexual 
relationships. These may substantially reduce the risk of active 
genital chlamydial infection.
This study found that females in the infertility group had 
a higher prevalence of chlamydia antibody compared with 
the control group. An infertile female was four times more 
likely to have chlamydial antibody than a female without 
infertility (95% CI: 1.47–10.88). This supports an etiological 
role for chlamydia infection.[6,16,17] It also further showed 
that females with tubal infertility had a higher prevalence of 
chlamydia antibody compared with those with patent tubes. 
Females with tubal infertility were three and a half times 
more likely to have evidence of past chlamydia infection than 
infertile females with patent tubes. This finding lays credence 
to the observations that C. trachomatis infection is a major 
etiological agent in tubal infertility.[5,6]
It is observed from this study that even infertility patients 
with patent tubes had a higher prevalence of chlamydia 
seropositivity (15.0%) compared with the control group (8.3%). 
This may suggest that apart from gross tubal blockage, 
chlamydia infection affect fertility in other ways, for example, 
by effecting other subtle damages in the cervix and on tubal 
architectural and functional integrity.[2]
Secondary infertility was the predominant type in this study 
accounting for 74.2% of the infertility group. Chlamydial 
antibody seropositivity was higher in those with primary 
infertility (32.3%) compared with the secondary type (24.7%). 
This suggests that chlamydial infection plays a more 
prominent role in the etiology of primary than secondary 
infertility.
Conclusion
The findings from this study suggest that chlamydia infection 
represents a major etiological factor for infertility particularly 
tubal infertility. It appears that affected individuals contract 
the infection in the early reproductive years. The reproductive 
health needs of young adults therefore should address the 
prevention, detection, and effective treatment of sexually 
transmitted infection alongside the need for effective 
contraception.
Limitations of the study
This was a facility-based study. Majority of participants in this 
study were referred and may have had different treatments 
especially antibiotic therapy before presentation in LUTH. The 
results obtained may therefore not be truly representative 
of prevalence of chlamydial antigen or antibody in infertile 
females in the community.
The most sensitive tests for chlamydial antigen are the 
nucleic acid amplification techniques (NAAT), for example, 
with PCR. The prohibitive costs of these however make them 
inappropriate as a screening tool in our environment hence 
the use of ELISA. The possibility of a few false negative results 
can therefore be speculated because of the lower sensitivity 
of ELISA. Laparoscopy is the gold-standard for the assessment 
of tubal patency. Its cost and invasiveness however limit 
its routine use. Hysterosalpingography (HSG), a cheaper, 
less invasive, and generally acceptable practical method of 
diagnosis was used in this study.
Recommendation
Reducing the burden of tubal infertility demands adequate 
attention to the predisposing events, which are largely 
preventable causes like chlamydial infection. However, 
noting that high sero-prevalence is often associated with 
low-antigen prevalence among infertile females with tubal 
diseases, effective preventive strategies should focus on 
detection and eradication of lower genital tract infection in 
adolescent girls and young females among whom the risk of 
infection is highest.
This study has not found any need for routine screening or 
prophylactic treatment for genital C. trachomatis infection 
among infertile females before procedures like HSG. However, 
a large community-based study of genital chlamydial infection 
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among infertile females will be required to fully address this 
issue.
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